Comparative Pharmacology
Head-to-head clinical analysis: DECABID versus TELDRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECABID versus TELDRIN.
DECABID vs TELDRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Decabid is a combination of chlorpheniramine (antihistamine) and pseudoephedrine (decongestant). Chlorpheniramine competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine acts as a sympathomimetic agent, stimulating alpha-adrenergic receptors to cause vasoconstriction, reducing nasal congestion.
TELDRIN contains loratadine and pseudoephedrine. Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonism. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction.
1 capsule orally every 12 hours; each capsule contains 10 mg phenylephrine hydrochloride and 75 mg carbinoxamine maleate.
1-2 mg orally twice daily; maximum 4 mg/day.
None Documented
None Documented
12 hours (terminal); prolonged to 24 hours in renal impairment (CrCl <30 mL/min)
Terminal half-life: 9-12 hours (range 8-14) in healthy adults; prolonged in renal impairment.
Renal (50% as unchanged drug), fecal (40% as metabolites), biliary (10% as glucuronide conjugates)
Renal: 55-60% unchanged; fecal: 35-40%; minor biliary elimination.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine